DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

Syphilis and gonorrhoea diagnoses see significant increase

Syphilis and gonorrhoea diagnoses see significant increase

June 11 2018 Annual reporting of sexually transmitted infection diagnoses has increased 0.3% in...

Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 26 2018 Women and girls of childbearing potential must no longer take valproate medicines...

  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:11
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:42
  • Syphilis and gonorrhoea diagnoses see significant increase

    Syphilis and gonorrhoea diagnoses see significant increase

    Monday, 11 June 2018 14:16
  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Thursday, 26 April 2018 11:48

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

aspirin pill bigApril 13 2016

Adults in their 50s should take low-dose aspirin for the primary prevention of cardiovascular disease and colorectal cancer, an independent US expert panel has recommended.

Patients in this age group for whom the recommendation applies are those who have a 10% or greater 10-year CVD risk or are at average risk of colorectal cancer, are not at increased risk of bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin for at least 10 years.

The recommendation has been made by the US Preventive Services Task Force, “an independent, volunteer panel of national experts in prevention and evidence-based medicine.” It has assessed the available evidence for aspirin use for people in their 50s as grade B. This suggests either that there is high certainty that the net benefit is moderate or that there is moderate certainty that the net benefit is moderate to substantial.

The evidence for low-dose aspirin’s use in people in their 60s is slightly lower, prompting the USPSTF to say: “The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one.

“Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to initiate low-dose aspirin,” the USPSTF said. It has not made any recommendations on low-dose aspirin for people under 50 or over 70.

Setting out its analysis of the data, the Task Force said that it had found adequate evidence that aspirin is of “moderate benefit” to reduce the risk of cardiovascular events such as nonfatal myocardial infarction and stroke in adults in their 50s and of increased CVD risk. It also found that aspirin use reduces the risk of colorectal cancer after five to ten years of use.

While aspirin can increase the risk of gastrointestinal bleeding and haemorrhagic stroke, it said “the harms vary but are small in adults aged 59 years or younger and small to moderate in adults aged 60 to 69 years. The USPSTF found inadequate evidence to determine the harms of aspirin use in adults aged 70 years or older.”

The USPSTF had consulted on a draft recommendation last autumn. It has published the final recommendation in the Annals of Internal Medicine on April 12 2016.

Links:

USPSTF recommendation summary

USPSTF Final Recommendation Statement

K Bibbins-Domingo et al. ‘Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement’. Ann Intern Med. Published online April 12 2016

Clinical News

July 20 2018 Community pharmacy representatives have briefed MPs about the role pharmacy teams can play in helping manage long term conditions.
July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued. The MHRA has launched the consultation with...